William P. Hales, Chairman, President and CEO, of Hemagen Diagnostics, Inc., (OTCBB: HMGN) (the “Company”) today announced the successful completion of its Exchange Offer for $4,049,858.01 in principal amount of the outstanding 8% Senior Subordinated Secured Convertible Notes due September 30, 2009 (the “Old Notes”). Those tendering in the Exchange Offer received new 8% Senior Subordinated Secured Convertible Notes due September 30, 2014 (the “New Notes”) having the same principal amount as the Old Notes tendered for exchange. The Exchange Offer expired on Wednesday September 30, 2009, at Midnight and is effective as of that date. The Company has accepted all Old Notes tendered for exchange.

This News Bulletin is neither an offer to purchase nor a solicitation of an offer to sell securities of Hemagen Diagnostics, Inc. The exchange offer will be made only through and upon the terms and conditions described in Hemagen Diagnostics, Inc’s, Offering Memorandum dated September 1, 2009, and related letter of transmittal. Hemagen has filed a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission. The Tender Offer Statement (including an offering circular, a related letter of transmittal and other offering documents) contains important information that should be read carefully before any decision is made with respect to the offer. The offering circular, the related letter of transmittal and certain other documents are being sent to all holders of Hemagen, Outstanding Notes, at no expense to them. The Tender Offer Statement (including the offering circular, the related letter of transmittal and all other documents filed with the Securities and Exchange Commission) are available at no charge at the Securities and Exchange Commission website at http://sec.gov or from Hemagen at cdavidson@hemagen.com.

Investors may also contact Mr. Hales, or Ms. Davidson at Hemagen Diagnostics, Inc., to obtain information about the exchange offer, including copies of the offering circular and related documents.

Hemagen Diagnostics (CE) (USOTC:HMGN)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Hemagen Diagnostics (CE) Charts.
Hemagen Diagnostics (CE) (USOTC:HMGN)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Hemagen Diagnostics (CE) Charts.